000144790 001__ 144790
000144790 005__ 20240229112637.0
000144790 0247_ $$2doi$$a10.1186/s12885-019-6102-6
000144790 0247_ $$2pmid$$apmid:31519152
000144790 037__ $$aDKFZ-2019-02222
000144790 041__ $$aeng
000144790 082__ $$a610
000144790 1001_ $$0P:(DE-He78)b2015e522a418c3350d3af1da8790aeb$$aDas, Krishna$$b0$$eFirst author$$udkfz
000144790 245__ $$aA transplantable tumor model allowing investigation of NY-BR-1-specific T cell responses in HLA-DRB1*0401 transgenic mice.
000144790 260__ $$aHeidelberg$$bSpringer$$c2019
000144790 3367_ $$2DRIVER$$aarticle
000144790 3367_ $$2DataCite$$aOutput Types/Journal article
000144790 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1575533536_28477
000144790 3367_ $$2BibTeX$$aARTICLE
000144790 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000144790 3367_ $$00$$2EndNote$$aJournal Article
000144790 520__ $$aNY-BR-1 has been described as a breast cancer associated differentiation antigen with intrinsic immunogenicity giving rise to endogenous T and B cell responses. The current study presents the first murine tumor model allowing functional investigation of NY-BR-1-specific immune responses in vivo.A NY-BR-1 expressing tumor model was established in DR4tg mice based on heterotopic transplantation of stable transfectant clones derived from the murine H2 compatible breast cancer cell line EO771. Composition and phenotype of tumor infiltrating immune cells were analyzed by qPCR and FACS. MHC I binding affinity of candidate CTL epitopes predicted in silico was determined by FACS using the mutant cell line RMA-S. Frequencies of NY-BR-1 specific CTLs among splenocytes of immunized mice were quantified by FACS with an epitope loaded Db-dextramer. Functional CTL activity was determined by IFNγ catch or IFNγ ELISpot assays and statistical analysis was done applying the Mann Whitney test. Tumor protection experiments were performed by immunization of DR4tg mice with replication deficient recombinant adenovirus followed by s.c. challenge with NY-BR-1 expressing breast cancer cells.Our results show spontaneous accumulation of CD8+ T cells and F4/80+ myeloid cells preferentially in NY-BR-1 expressing tumors. Upon NY-BR-1-specific immunization experiments combined with in silico prediction and in vitro binding assays, the first NY-BR-1-specific H2-Db-restricted T cell epitope could be identified. Consequently, flow cytometric analysis with fluorochrome conjugated multimers showed enhanced frequencies of CD8+ T cells specific for the newly identified epitope in spleens of immunized mice. Moreover, immunization with Ad.NY-BR-1 resulted in partial protection against outgrowth of NY-BR-1 expressing tumors and promoted intratumoral accumulation of macrophages.This study introduces the first H2-Db-resctricted CD8+ T cell epitope-specific for the human breast cancer associated tumor antigen NY-BR-1. Our novel, partially humanized tumor model enables investigation of the interplay between HLA-DR4-restricted T cell responses and CTLs within their joint attack of NY-BR-1 expressing tumors.
000144790 536__ $$0G:(DE-HGF)POF3-314$$a314 - Tumor immunology (POF3-314)$$cPOF3-314$$fPOF III$$x0
000144790 588__ $$aDataset connected to CrossRef, PubMed,
000144790 7001_ $$0P:(DE-He78)3ef7e82c44147a46608c74c80e77ffc9$$aEisel, David$$b1$$udkfz
000144790 7001_ $$aVormehr, Mathias$$b2
000144790 7001_ $$0P:(DE-He78)799d978330dff449f8244947929a4518$$aMüller-Decker, Karin$$b3$$udkfz
000144790 7001_ $$0P:(DE-HGF)0$$aHommertgen, Adriane$$b4
000144790 7001_ $$0P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1$$aJäger, Dirk$$b5$$udkfz
000144790 7001_ $$aZörnig, Inka$$b6
000144790 7001_ $$aFeuerer, Markus$$b7
000144790 7001_ $$0P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aKopp-Schneider, Annette$$b8$$udkfz
000144790 7001_ $$0P:(DE-He78)b757b21d60bbaa4164899bb7e61b0c15$$aOsen, Wolfram$$b9$$udkfz
000144790 7001_ $$0P:(DE-He78)23fb8cfffbf2aa8eee5d51af417ad944$$aEichmüller, Stefan$$b10$$eLast author$$udkfz
000144790 773__ $$0PERI:(DE-600)2041352-X$$a10.1186/s12885-019-6102-6$$gVol. 19, no. 1, p. 914$$n1$$p914$$tBMC cancer$$v19$$x1471-2407$$y2019
000144790 909CO $$ooai:inrepo02.dkfz.de:144790$$pVDB
000144790 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b2015e522a418c3350d3af1da8790aeb$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000144790 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3ef7e82c44147a46608c74c80e77ffc9$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000144790 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)799d978330dff449f8244947929a4518$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000144790 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000144790 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000144790 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000144790 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b757b21d60bbaa4164899bb7e61b0c15$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000144790 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)23fb8cfffbf2aa8eee5d51af417ad944$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000144790 9131_ $$0G:(DE-HGF)POF3-314$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTumor immunology$$x0
000144790 9141_ $$y2019
000144790 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBMC CANCER : 2017
000144790 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000144790 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000144790 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000144790 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000144790 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000144790 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000144790 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Open peer review
000144790 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000144790 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000144790 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000144790 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000144790 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000144790 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000144790 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000144790 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000144790 9201_ $$0I:(DE-He78)D210-20160331$$kD210$$lArbeitsgruppe GMP & T-Zelltherapie$$x0
000144790 9201_ $$0I:(DE-He78)W420-20160331$$kW420$$lTumormodelle$$x1
000144790 9201_ $$0I:(DE-He78)D120-20160331$$kD120$$lAngewandte Tumor-Immunität$$x2
000144790 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x3
000144790 980__ $$ajournal
000144790 980__ $$aVDB
000144790 980__ $$aI:(DE-He78)D210-20160331
000144790 980__ $$aI:(DE-He78)W420-20160331
000144790 980__ $$aI:(DE-He78)D120-20160331
000144790 980__ $$aI:(DE-He78)C060-20160331
000144790 980__ $$aUNRESTRICTED